A self-assembled nanoparticle, its preparation method and application

By combining taxane and oleanolic acid into nanoparticles using self-assembled nanoparticle technology, the problems of low solubility and bioavailability of natural drugs are solved, achieving highly efficient antibacterial and immunomodulatory effects on intracellular S. aureus, alleviating inflammation, and expanding its application in the treatment of intracellular infections.

CN116602937BActive Publication Date: 2026-11-17HUAZHONG AGRI UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310589684.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2026-11-17
Estimated Expiration
2043-05-24

AI Technical Summary

Technical Problem

Existing antibiotics are difficult to penetrate the cell membrane barrier to enter cells and effectively inhibit or kill bacteria, and they also have drug resistance problems. Natural drugs have poor solubility and low bioavailability, which limits their application in the treatment of intracellular Staphylococcus aureus (S. aureus) infections.

Method used

Using self-assembled nanoparticle technology, natural active molecules taxane and oleanolic acid are combined and formed into nanoparticles through ultrasonic treatment and stirring, which enhances their antibacterial effect in cells. Stabilizers such as polyvinylpyrrolidone and solvents such as ethanol are added to improve solubility and bioavailability.

Benefits of technology

It enhances the antibacterial ability of natural drugs against intracellular S. aureus, reduces their number, and alleviates inflammation through immunomodulation. It also improves the solubility and clinical application of natural drugs, and is low-cost and does not require large equipment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116602937B_ABST
    Figure CN116602937B_ABST
Patent Text Reader

Abstract

This invention relates to the field of antibacterial drug preparation technology, and in particular to a self-assembled nanoparticle, its preparation method, and its application. The self-assembled nanoparticle comprises, by mass percentage, 0.17-0.24% of a natural active molecular composition; the natural active molecular composition includes natural active molecule A and natural active molecule B; natural active molecule A is one of sennaol, taxol, and chalcone; and natural active molecule B is one of ursolic acid, pterostilbene, and oleanolic acid. This invention, based on self-assembled nanoparticles of natural active molecules, can not only inhibit *S. aureus* invasion of host cells but also increase the intracellular concentration of natural drugs, thereby reducing the number of intracellular *S. aureus*, effectively solving the treatment problem of intracellular *S. aureus*; it can also promote macrophage polarization to the M2 phenotype, reduce the production of pro-inflammatory cytokines, and effectively alleviate the development of inflammation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of antibacterial drug preparation technology, and in particular to a self-assembled nanoparticle, its preparation method, and its application. Background Technology

[0002] Staphylococcus aureus (S. aureus) can survive and proliferate intracellularly through various specific survival strategies, such as escaping from phagosomes, preventing the binding of lysosomes and phagosomes to form phagolysosomes, and disrupting autophagy. This leads to secondary infection foci, making the infection difficult to cure and prone to recurrence. Currently, clinical treatment for intracellular S. aureus primarily relies on antibiotics. However, conventional antibacterial drugs often struggle to penetrate the cell membrane barrier to achieve effective bacteriostatic or bactericidal effects, and they exhibit poor intracellular retention and stability. Furthermore, the overuse of antibiotics has led to increasingly serious drug resistance. Therefore, new strategies are urgently needed for the treatment of intracellular S. aureus.

[0003] Sortase A (SrtA) is one of the most important virulence factors in S. aureus infection. It anchors various S. aureus surface proteins to the cell wall, playing a crucial role in S. aureus invasion. Various molecules capable of inhibiting SrtA have been reported, including small organic molecules, peptide analogs, and natural products. Natural drugs are widely studied due to their safety, stability, and strong SrtA inhibitory activity. However, generally speaking, SrtA inhibitors have weak antibacterial activity against S. aureus and cannot kill intracellular S. aureus. Therefore, the combination of SrtA inhibitors and antibacterial drugs effectively reduces the number of intracellular S. aureus. Studies have shown that natural drugs have advantages such as fewer side effects, lower residues, and stronger resistance to drug resistance, and have become an alternative to antibiotic therapy. However, natural drugs have disadvantages such as low bioavailability and poor solubility, which greatly limit their efficacy and clinical application. Therefore, the combined use of inhibiting S. aureus internalization and intracellular proliferation is of great significance for achieving efficient inhibition of intracellular S. aureus. Summary of the Invention

[0004] Based on the above, this invention provides a self-assembled nanoparticle, its preparation method, and its application, which can enhance the anti-intracellular S. aureus activity and immunomodulatory effects of natural active molecules (natural drugs), and solve the problems of poor solubility and low bioavailability of natural active molecules.

[0005] To achieve the above objectives, the present invention provides the following solution:

[0006] One of the technical solutions of the present invention is a self-assembled nanoparticle, wherein, by mass percentage, the self-assembled nanoparticle comprises 0.17-0.24% of a natural active molecular composition;

[0007] The natural active molecule composition includes natural active molecule A and natural active molecule B;

[0008] The natural active molecule A is one of sennaol, taxol, and chalcone; the natural active molecule B is one of ursolic acid, pterostilbene, and oleanolic acid.

[0009] Furthermore, the natural active molecular composition is a combination of taxane and oleanolic acid.

[0010] Furthermore, the natural active molecular composition is a composition of taxane and oleanolic acid in a mass ratio of 3.8-15.2:22.8.

[0011] Furthermore, by mass percentage, the self-assembled nanoparticles consist of 0.17-0.24% natural active molecular composition, 1.5-2.25% stabilizer, 25% solvent and the balance water.

[0012] Furthermore, the stabilizer is one of polyvinyl alcohol, poloxamer 188, and polyvinylpyrrolidone.

[0013] Furthermore, the solvent is one of methanol, dimethyl sulfoxide, ethanol, and isopropanol.

[0014] The self-assembled nanoparticles prepared according to the above formula exhibit the best self-assembly efficiency, with oleanolic acid achieving a self-assembly rate of 90.82%-99.00% and taxine achieving a self-assembly rate of 34.78%-55.61%. Parameters exceeding or falling below the above-described ranges will affect the self-assembly efficiency.

[0015] The second technical solution of the present invention is a method for preparing the above-mentioned self-assembled nanoparticles, comprising the following steps:

[0016] Natural active molecule A and natural active molecule B are dissolved in a solvent to obtain solution A. Solution A is then added dropwise to a stabilizer aqueous solution, and the mixture is ultrasonically treated and stirred to obtain the self-assembled nanoparticles.

[0017] Further, the dripping is specifically performed by adding the solution at a stirring speed of 400-800 r / min and a titration rate of 1.0-2.0 mL / min; the ultrasonic treatment is specifically performed by ultrasonic treatment at a power of 180-360 W for 2-5 min; and the stirring time is 6-18 h.

[0018] The self-assembled nanoparticles prepared according to the parameter range described above exhibited the best particle size uniformity, with particle sizes ranging from 424.7 to 604.3 nm and dispersion indices from 0.281 to 0.333. The dispersion indices were all less than 0.5, indicating a uniform particle size distribution in the prepared self-assembled nanoparticles. Parameters higher or lower than the above range would affect the particle size uniformity of the self-assembled nanoparticles.

[0019] The third technical solution of the present invention is the application of the above-mentioned self-assembled nanoparticles in the preparation of drugs for treating intracellular bacterial infections and drugs for reducing or regulating bacterial infection inflammation.

[0020] The present invention discloses the following technical effects:

[0021] The preparation method of this invention is simple, requires no large-scale professional equipment, and is low in cost.

[0022] The self-assembled nanoparticles prepared in this invention not only inhibit S. aureus invasion of host cells but also increase the intracellular concentration of natural drugs, thereby reducing the number of intracellular S. aureus and effectively solving the treatment challenge of intracellular S. aureus. Furthermore, the self-assembled nanoparticles improve the solubility of natural drugs, expanding their clinical applications. More importantly, the self-assembled nanoparticles based on natural active molecules in this invention can promote macrophage polarization to the M2 phenotype, reduce the production of pro-inflammatory cytokines, effectively alleviate the development of inflammation, and contribute to inflammation resolution and tissue repair. Moreover, the anti-inflammatory effect of the self-assembled nanoparticles is superior to that of cefquinome sulfate intramuscular infusion. Attached Figure Description

[0023] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0024] Figure 1 The images are scanning electron microscope (SEM) images of the self-assembled nanoparticles 1-4 prepared with different organic reagents in Example 1.

[0025] Figure 2 The images are scanning electron microscope (SEM) images of self-assembled nanoparticles 3, 5, and 6 prepared with different stabilizers in Example 1.

[0026] Figure 3 This invention demonstrates the inhibitory effect of self-assembled nanoparticles 10 (OA-TAX NPs) on SrtA.

[0027] Figure 4This invention demonstrates the inhibitory effect of self-assembled nanoparticles 10 on the invasion of S. aureus; *** indicates a statistically significant difference compared to the control group; **** indicates a highly significant statistical difference compared to the control group.

[0028] Figure 5 This is a photograph of a plate of intracellular S. aureus after treatment with the self-assembled nanoparticles 10 of this invention.

[0029] Figure 6 This invention demonstrates the immunomodulatory effect of self-assembled nanoparticles 10. In the figure, A represents the protein expression levels of CD86 and CD206 induced by S. aureus induced by OA-TAX NPs as detected by Western blot; B represents the changes in inflammatory factors induced by S. aureus induced by OA-TAX NPs as detected by ELISA; in the figure, *** indicates a statistically significant difference compared to the control group; **** indicates a highly statistically significant difference compared to the control group.

[0030] Figure 7 The figures show the bacterial load in breast tissue of different treatment groups according to the present invention; *** indicates a statistically significant difference compared with the control group; **** indicates a statistically significant difference compared with the control group.

[0031] Figure 8 The histopathological changes of breast tissue in different treatment groups of this invention are shown.

[0032] Figure 9 This is a physical image of the self-assembled nanoparticles 10 of the present invention.

[0033] Figure 10 The images shown are electron microscope (EM) images of the self-assembled nanoparticles 10 of the present invention; the left image is a scanning electron microscope (SEM) image of the self-assembled nanoparticles 10 (scale bar: 10 μm), and the right image is a transmission electron microscope (TEM) image of the self-assembled nanoparticles 10 (scale bar: 200 nm).

[0034] Figure 11 This is a particle size distribution diagram of the self-assembled nanoparticles 10 of the present invention. Detailed Implementation

[0035] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0036] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any stated value or intermediate value within a stated range, as well as each smaller range between any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0037] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0038] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be apparent to those skilled in the art. This specification and embodiments are merely exemplary.

[0039] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0040] Example 1

[0041] 1. Fractionated antibacterial concentrations (FICs) of natural active molecule complexes

[0042] 1.1 The natural active molecular composition in the self-assembled nanoparticles is shown in Table 1. The relationship between natural active molecules was determined by the fractional inhibitory concentration (FIC). The FIC indexes ≤0.5, >0.5~1, >1~2, and >2 represent synergistic, additive, unrelated, and antagonistic effects, respectively.

[0043] Table 1 Natural Active Molecule Formulation Combinations

[0044]

[0045] The specific method includes the following steps:

[0046] (1) Using 96-well sterile microplates, each drug was serially diluted with sterile LB broth to obtain 7 dilutions: 256 μg / mL, 128 μg / mL, 64 μg / mL, 32 μg / mL, 16 μg / mL, 8 μg / mL, and 4 μg / mL.

[0047] (2) Take 50 μL of each and arrange them in rows and columns of the plate, then add 100 μL to the sterile microplate to dilute to 1.5 × 10⁻⁶. 6 The bacterial suspension was diluted to CFU / mL, resulting in a final inoculum size of 1.5 × 10⁻⁶. 6 The minimum drug concentration at which no bacterial growth is achieved after overnight incubation (CFU / mL) is defined as the MIC.

[0048] (3) Calculate the FIC index of the combination drugs. FIC index = MIC(Molecule A combined) / MIC(Molecule A alone) + MIC(Molecule B combined) / MIC(Molecule B alone).

[0049] 1.2 The FIC test results of different formulations of natural active molecular compositions are shown in Table 2.

[0050] Table 2. Graded antibacterial concentration index of different formulations in Example 1

[0051]

[0052]

[0053] As shown in Table 2, the inhibitory effects of oleanolic acid and taxol on S. aureus are additive.

[0054] 2. Preparation method of self-assembled nanoparticles

[0055] 2.1 Self-assembled nanoparticles prepared with different organic reagents and their morphological characteristics

[0056] 2.1.1 Preparation process of self-assembled nanoparticles with different organic reagents

[0057] (1) 22.8 mg of oleanolic acid and 15.2 mg of taxin were heated and dissolved in 4 mL of methanol. The mixture was stirred to ensure complete dissolution of both drugs, resulting in solution 1. Solution 1 was slowly added to 12 mL of 2% polyvinylpyrrolidone solution at a titration rate of 2 mL / min and a stirring rate of 800 r / min. The mixture was then ultrasonically treated with a 600 W ultrasonic disruptor at 60% power for 5 min and stirred continuously for 6 h to obtain self-assembled nanoparticles 1.

[0058] (2) 22.8 mg of oleanolic acid and 15.2 mg of taxin were heated and dissolved in 4 mL of dimethyl sulfoxide. The mixture was stirred until both drugs were fully dissolved to obtain solution 2. Solution 2 was slowly added to 12 mL of 2% polyvinylpyrrolidone solution at a titration rate of 2 mL / min and a stirring rate of 800 r / min. The mixture was then ultrasonically treated with a 600 W ultrasonic disruptor at 60% power for 5 min and stirred continuously for 6 h to obtain self-assembled nanoparticles 2.

[0059] (3) 22.8 mg of oleanolic acid and 15.2 mg of taxin were heated and dissolved in 4 mL of ethanol. The mixture was stirred to ensure complete dissolution of both drugs, resulting in solution 3. Solution 3 was slowly added to 12 mL of 2% polyvinylpyrrolidone solution at a titration rate of 2 mL / min and a stirring rate of 800 r / min. The mixture was then ultrasonically treated with a 600 W ultrasonic disruptor at 60% power for 5 min and stirred continuously for 6 h to obtain self-assembled nanoparticles 3.

[0060] (4) 22.8 mg of oleanolic acid and 15.2 mg of taxin were heated and dissolved in 4 mL of isopropanol. The mixture was stirred until both drugs were fully dissolved to obtain solution 4. Solution 4 was slowly added to 12 mL of 2% polyvinylpyrrolidone solution at a titration rate of 2 mL / min and a stirring rate of 800 r / min. The mixture was then ultrasonically treated with a 600 W ultrasonic disruptor at 60% power for 5 min and stirred continuously for 6 h to obtain self-assembled nanoparticles 4.

[0061] 2.1.2 Morphological characteristics of self-assembled nanoparticles prepared with different organic reagents

[0062] Scanning electron microscopy images of self-assembled nanoparticles prepared with different organic reagents are shown below. Figure 1 As shown.

[0063] from Figure 1 It can be seen that nanoparticle 1 has an irregular shape and is adhered to each other; nanoparticle 2 is spherical and not very uniform in size; nanoparticle 3 has a spherical structure with a particle size of about 200 nm; and nanoparticle 4 has a particle size of about 1 μm. Therefore, ethanol was chosen as the organic reagent for the subsequent preparation of nanoparticles.

[0064] 2.2 Self-assembled nanoparticles prepared with different stabilizers and their morphological characteristics

[0065] 2.2.1 Preparation process of self-assembled nanoparticles with different stabilizers

[0066] (1) 22.8 mg of oleanolic acid and 15.2 mg of taxin were heated and dissolved in 4 mL of ethanol. The mixture was stirred to ensure complete dissolution of both drugs, resulting in solution 3. Solution 3 was slowly added to 12 mL of 2% polyvinylpyrrolidone solution at a titration rate of 2 mL / min and a stirring rate of 800 r / min. The mixture was then ultrasonically treated with a 600 W ultrasonic disruptor at 60% power for 5 min and stirred continuously for 6 h to obtain self-assembled nanoparticles 3.

[0067] (2) 22.8 mg of oleanolic acid and 15.2 mg of taxin were heated and dissolved in 4 mL of ethanol. The mixture was stirred to ensure complete dissolution of both drugs, resulting in solution 3. Solution 3 was slowly added to 12 mL of 2% polyvinyl alcohol solution at a titration rate of 2 mL / min and a stirring rate of 800 r / min. The mixture was then ultrasonically treated with a 600 W ultrasonic disruptor at 60% power for 5 min and stirred continuously for 6 h to obtain self-assembled nanoparticles 5.

[0068] (3) 22.8 mg of oleanolic acid and 15.2 mg of taxin were heated and dissolved in 4 mL of ethanol. The mixture was stirred to ensure complete dissolution of both drugs, resulting in solution 3. Solution 3 was slowly added to 12 mL of 2% poloxamer 188 solution at a titration rate of 2 mL / min and a stirring rate of 800 r / min. The mixture was then sonicated at 60% power using a 600 W ultrasonic disruptor for 5 min and stirred continuously for 6 h to obtain self-assembled nanoparticles 6.

[0069] 2.2.2 Morphological characteristics of self-assembled nanoparticles prepared with different stabilizers

[0070] Scanning electron microscopy images of self-assembled nanoparticles prepared with different stabilizers are shown below. Figure 2 As shown.

[0071] Depend on Figure 2 It can be seen that nanoparticles prepared with polyvinyl alcohol as a stabilizer are prone to aggregation, while nanoparticles prepared with polyvinylpyrrolidone and poloxamer 188 as stabilizers are uniform in size, and poloxamer 188 has a lower cost. Therefore, poloxamer 188 was selected as the stabilizer for subsequent nanoparticle preparation.

[0072] 2.3 Preparation, particle size, and polydispersity index (PDI) of self-assembled nanoparticles with different stabilizer contents

[0073] 2.3.1 Preparation process of self-assembled nanoparticles with different stabilizer contents

[0074] (1) 22.8 mg of oleanolic acid and 15.2 mg of taxin were heated and dissolved in 4 mL of ethanol. The mixture was stirred to ensure complete dissolution of both drugs, resulting in solution 3. Solution 3 was slowly added to 12 mL of 2% poloxamer 188 solution at a titration rate of 1 mL / min and a stirring rate of 800 r / min. The mixture was then sonicated at 60% power using a 600 W ultrasonic disruptor for 5 min and stirred continuously for 18 h to obtain self-assembled nanoparticles 7.

[0075] (2) 22.8 mg of oleanolic acid and 15.2 mg of taxin were heated and dissolved in 4 mL of ethanol. The mixture was stirred to ensure complete dissolution of both drugs, resulting in solution 3. Solution 3 was slowly added to 12 mL of 2.5% poloxamer 188 solution at a titration rate of 1 mL / min and a stirring rate of 800 r / min. The mixture was then sonicated at 60% power using a 600 W ultrasonic disruptor for 3 min and stirred continuously for 16 h to obtain self-assembled nanoparticles 8.

[0076] (3) 22.8 mg of oleanolic acid and 15.2 mg of taxin were heated and dissolved in 4 mL of ethanol. The mixture was stirred to ensure complete dissolution of both drugs, resulting in solution 3. Solution 3 was slowly added to 12 mL of 3% poloxamer 188 solution at a titration rate of 1 mL / min and a stirring rate of 500 r / min. The mixture was then ultrasonically treated with a 600 W ultrasonic disruptor at 60% power for 2 min and stirred continuously for 12 h to obtain self-assembled nanoparticles 9.

[0077] 2.3.2 Particle size and PDI of self-assembled nanoparticles with different stabilizer contents

[0078] Table 3. Particle size and PDI of self-assembled nanoparticles prepared with different stabilizer contents.

[0079]

[0080] As can be seen from Table 3, the nanoparticles containing 3% poloxamer 188 have the smallest particle size and a uniform particle size distribution.

[0081] This invention also verified the case where the poloxamer 188 content exceeded 3%. The results showed that when the poloxamer 188 content exceeded 3%, after sonication, it became a jelly-like liquid, not a suspension of self-assembled nanoparticles.

[0082] 2.4 Preparation, Assembly Rate and Characterization of Self-Assembled Nanoparticles with Different Drug Ratios

[0083] 2.4.1 Preparation process of self-assembled nanoparticles with different drug ratios

[0084] (1) 22.8 mg of oleanolic acid and 15.2 mg of taxin were heated and dissolved in 4 mL of ethanol. The mixture was stirred to ensure complete dissolution of both drugs, resulting in solution 3. Solution 3 was slowly added to 12 mL of 3% poloxamer 188 solution at a titration rate of 1 mL / min and a stirring rate of 500 r / min. The mixture was then sonicated at 60% power using a 600 W ultrasonic disruptor for 2 min and stirred continuously for 12 h to obtain self-assembled nanoparticles 9.

[0085] (2) 22.8 mg of oleanolic acid and 7.6 mg of taxin were heated and dissolved in 4 mL of ethanol. The mixture was stirred to fully dissolve the two drugs to obtain solution 5. Under the conditions of titration speed of 1 mL / min and stirring speed of 500 r / min, solution 5 was slowly added to 12 mL of 3% poloxamer 188 solution. The mixture was ultrasonically treated with 40% power of a 600W ultrasonic disruptor for 2 min and stirred continuously for 12 h to prepare self-assembled nanoparticles 10.

[0086] Figure 9 This is a physical image of the self-assembled nanoparticles 10 of the present invention.

[0087] Figure 10 These are electron microscope (EM) images of the self-assembled nanoparticles 10 of the present invention; the left image is a scanning electron microscope (SEM) image of the self-assembled nanoparticles 10 (scale bar: 10 μm), and the right image is a transmission electron microscope (TEM) image of the self-assembled nanoparticles 10 (scale bar: 200 nm). Figure 10 It can be seen that the self-assembled nanoparticles 10 have a spherical structure and are relatively uniform in size.

[0088] Figure 11 This is a particle size distribution diagram of the self-assembled nanoparticles 10 of the present invention. Figure 11 It can be seen that the particle size of the self-assembled nanoparticle 10 is about 400 nm.

[0089] (3) 22.8 mg of oleanolic acid and 3.8 mg of taxin were heated and dissolved in 4 mL of ethanol. The mixture was stirred to fully dissolve the two drugs to obtain solution 6. Under the conditions of titration speed of 1 mL / min and stirring speed of 400 r / min, solution 6 was slowly added to 12 mL of 3% poloxamer 188 solution. The mixture was ultrasonically treated with 30% power of a 600W ultrasonic disruptor for 2 min and stirred continuously for 12 h to prepare self-assembled nanoparticles 11.

[0090] 2.4.2 Determination of Assembly Rate of Self-Assembled Nanoparticles with Different Drug Ratios

[0091] Self-assembled nanoparticles were prepared according to the above process, and the assembly rates of oleanolic acid (OA) and taxine (TAX) were determined. The prepared nanoparticles were centrifuged at 12000 r / min for 40 min at 4 °C. The precipitate after centrifugation was washed three times with double-distilled water. The free OA and TAX in the supernatant were determined by high-performance liquid chromatography, and the assembly rate was calculated indirectly.

[0092] (1) Assembly rate (AR) is calculated according to the following formula:

[0093]

[0094] Where N0 represents the initial quantity of OA / TAX, N t This indicates the amount of OA / TAX in the supernatant after centrifugation.

[0095] (2) Establishment of liquid chromatography detection methods for OA and TAX

[0096] TAX: The chromatographic column is C10. 18 The column temperature was 35℃, the injection volume was 10μL, the mobile phase was 0.1% acetic acid (A) and methanol (B), the flow rate was 0.8mL / min, and the mobile phase ratio was A:B = 30:70; the detection wavelength was 290nm.

[0097] OA: The chromatographic column is C10. 18 The column temperature was 30℃, the injection volume was 20μL, the mobile phase was 0.5% ammonium acetate (A) and methanol (B), the flow rate was 0.6mL / min, and the mobile phase ratio was A:B = 10:90; the detection wavelength was 210nm.

[0098] Within the range of 10–80 μg / mL, the regression equation for the OA standard solution is y = 14874x - 29889, R0 2 =0.9984; In the range of 5–50 μg / mL, the regression equation for the TAX standard solution is y = 104682x + 4962, R 2 =0.9997.

[0099] (3) Results

[0100] Table 4 Assembly rate of self-assembled nanoparticles with different drug ratios

[0101]

[0102] 2.4.3 Particle size and PDI of self-assembled nanoparticles with different drug ratios

[0103] Table 5. Particle size and PDI of self-assembled nanoparticles with different drug ratios

[0104]

[0105] In summary, when the molar ratio of oleanolic acid to taxane was 2:1, taxane exhibited the highest assembly rate, smallest particle size, and most uniform size. Therefore, self-assembled nanoparticles 10 were selected for subsequent anti-intracellular bacterial and immunomodulatory experiments.

[0106] Effect verification example

[0107] 1. Inhibitory effect of self-assembled nanoparticles 10 on SrtA

[0108] 1.1 Test Methods

[0109] The inhibitory effect of drugs on SrtA was investigated using FRET. The experiment was performed in 96-well plates with a total reaction volume of 300 μL. 30 μmol / L purified recombinant SrtA protein was mixed with 32 μg / mL of OA, TAX, a physical mixture of OA and TAX (OA+TAX, with the concentrations and ratios of OA and TAX in the solution the same as for self-assembled nanoparticles 10), OA-TAX NPs (self-assembled nanoparticles 10), and reaction buffer, and incubated at 37°C for 2 h. Then, a substrate peptide was added to a final concentration of 10 μmol / L, and the mixture was incubated at 37°C for another 1 h. The fluorescence intensity was then measured at an excitation wavelength of 350 nm and an emission wavelength of 495 nm. Controls were set up with SrtA, buffer, and substrate peptide. The inhibition rate of different combinations on SrtA activity was calculated as 100% × (CT) / C, where C is the fluorescence value of the untreated group and T is the fluorescence value of the experimental group.

[0110] 1.2 Results

[0111] SrtA recognizes and cleaves the Abz-LPATG-Dap(Dnp)NH2 motif, causing a change in fluorescence signal. FRET was used to investigate the inhibitory effects of 32 μg / mL OA, TAX, OA+TAX, and OA-TAX NPs on SrtA. Results are as follows: Figure 3 As shown, by Figure 3 It can be seen that OA has almost no inhibitory effect on SrtA. Furthermore, OA+TAX and OA-TAX NPs show almost the same inhibition rate on SrtA. Compared with an equivalent amount of TAX, OA+TAX and OA-TAX NPs show higher inhibition rates on SrtA than TAX alone, indicating that OA does not affect the inhibitory effect of TAX on SrtA.

[0112] 2. Inhibitory effect of self-assembled nanoparticles on the invasion of S. aureus

[0113] 2.1 Test Methods

[0114] First, *S. aureus* was cultured in LB broth at 37°C to OD600 = 1.0 with 16 μg / mL taxane (TAX), oleanolic acid (OA), OA+TAX, and OA-TAXNPs. Untreated *S. aureus* was used as a negative control (WT), and ΔSrtA_ was used as a positive control. Then, cells inoculated in 24 wells were mixed with *Staphylococcus aureus* at a 10:1 multiple of infection (MOI) and incubated at 37°C and 5% CO2 for 2 h. Next, the wells were washed three times with PBS (pH = 7.4) to remove non-adhesive bacteria, and gentamicin was added and the cells were co-incubated for 1 h to eradicate extracellular bacteria. Finally, the cells were washed three times with PBS and lysed using Triton X-100. The lysates were diluted with PBS and plated in triplicate on LB agar plates, and colony-forming units (CFU) were manually counted.

[0115] 2.2 Results

[0116] The number of *S. aureus* colonies invading MAC-T cells is as follows: Figure 4 As shown. By Figure 4 It can be seen that the number of bacterial colonies in MAC-T cells was significantly reduced in the ΔSrtA group compared with the WT group (p<0.0001). Treatment with 16 μg / mL OA, TAX, OA+TAX, and OA-TAX NPs with *S. aureus* resulted in a decreasing trend in intracellular bacteria. Among these, OA-TAX NPs significantly inhibited the invasion of *S. aureus* into MAC-T cells (p<0.0001). Therefore, OA-TAX NPs enhanced its ability to enter the cell, further reducing the number of *S. aureus* within the cell.

[0117] 3. Inhibitory effect of self-assembled nanoparticles on intracellular S. aureus

[0118] 3.1 Test Methods

[0119] MAC-T cells were seeded in 24-well plates and incubated at 37°C with 5% CO2 for 24 hours. After centrifugation, the logarithmic-phase bacterial culture was washed three times with sterile PBS. The bacteria were then added to adherent MAC-T cell culture plates. After incubation at 37°C for 2 hours, the culture medium was removed, and the cells were washed three times with sterile PBS. Then, medium containing gentamicin was added and cultured for 1 hour to remove extracellular bacteria. 1 mL of fresh medium containing 32 μg / mL OA, TAX, OA+TAX, and OA-TAX NPs was added to pre-cultured S. aureus-infected MAC-T cells in wells, mixed thoroughly, and incubated for 24 hours. The culture medium was then removed, the cells were washed three times with ice-cold PBS, and lysed using Triton X-100. The lysates were plated on LB agar plates, and CFU were manually counted to calculate the intracellular bacterial survival after different drug treatments.

[0120] 3.2 Results

[0121] Photographs of intracellular bacteria plated after drug treatment are shown below. Figure 5 As shown. By Figure 5 It was found that OA and an equal volume of OA+TAX mixed solution had some scavenging ability against intracellular S. aureus. Since the MIC of TAX against S. aureus is 512 μg / mL, 32 μg / mL of TAX had almost no antibacterial activity against intracellular S. aureus. Compared with the OA+TAX mixed solution, the number of intracellular bacteria in OA-TAX NPs was significantly reduced (p<0.001). These results indicate that OA-TAX NPs increase the effective concentration of intracellular OA, thereby enhancing their ability to resist intracellular S. aureus.

[0122] 4. Immunomodulatory effects of self-assembled nanoparticles

[0123] Macrophages (RAW264.7) are effector cells that fight infection and inflammation, and their polarization direction directly determines their function. RAW264.7 cells can differentiate into pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes. M1 phenotype RAW264.7 cells produce high levels of pro-inflammatory cytokines, thereby equipping the host with the ability to defend against intracellular pathogens. Conversely, M2 phenotype RAW264.7 cells release anti-inflammatory cytokines, promoting the proliferation of adjacent cells and tissue repair. To investigate the immunomodulatory effects of OA-TAX NPs on RAW264.7 cells, M1 phenotype markers (iNOS, TNF-α, IL-1β, IL-6, CD86) and M2 phenotype markers (IL-4, IL-10, CD206) were selected, and the expression of related cytokines was detected by ELISA and Western blot, respectively.

[0124] 4.1 Test Methods

[0125] RAW264.7 cells were seeded in 24-well plates and cultured at 37°C for 24 h under 5% CO2 conditions. Cells were then mixed with *S. aureus* at a 10:1 MOI and infected for 2 h, after which the culture medium was discarded. Cells were then incubated with 32 μg / mL OA, TAX, OA+TAX, and OA-TAX NPs, respectively, for 24 h. Complete culture medium was added after bacterial infection as a negative control. Western blot was used to detect the expression levels of immunomodulatory marker proteins. Simultaneously, ELISA was used to detect changes in inflammatory factors in the cell supernatant.

[0126] 4.2 Results

[0127] Figure 6 In figure A, Western blot analysis shows the inhibitory effect of OA-TAX NPs on S. aureus-induced pro-inflammatory cytokines; in figure B, ELISA analysis shows the effect of OA-TAX NPs on the changes in S. aureus-induced inflammatory factors. Figure 6 As shown in the results of the study, compared with the control group, the OA, TAX, OA+TAX, and OA-TAX NPs groups showed reduced secretion of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, and iNOS) and increased secretion of anti-inflammatory cytokines (IL-4 and IL-10). Furthermore, Western blot results indicated that all drug treatment groups exhibited upregulation of M2 marker expression compared with the control group. The OA-TAX NPs group showed a significant upregulation of CD206 protein expression (…). Figure 6 (A). In summary, the above results indicate that OA-TAX NPs can not only inhibit S. aureus-induced inflammation, but also positively regulate macrophage polarization from the M1 phenotype to the M2 phenotype, demonstrating the significant potential of OA-TAX NPs in treating intracellular bacterial infections and resolving inflammation.

[0128] 5. Pharmacodynamics of self-assembled nanoparticles

[0129] 5.1 Materials and Methods

[0130] (1) Drugs: OA, TAX, OA+TAX, OA-TAX NPs, cefquinoxime sulfate intramuscular injection (TB).

[0131] (2) Experimental animals: 36 mice, which were housed in separate cages at the Experimental Animal Center of Huazhong Agricultural University.

[0132] (3) Test methods

[0133] The experiment was conducted in strict accordance with animal welfare principles, ensuring suitable temperature, sufficient feed, and free access to water. *S. aureus* (1.5 × 10⁻⁶) was used. 8 Cefquinoxime sulfate (CFU) was injected into the fourth pair of mammary ducts of mice, 100 μL per side. Twenty-four hours after challenge, mice were randomly divided into six groups: *S. aureus* (control group), OA, TAX, OA+TAX, OA-TAX NPs, and cefquinoxime sulfate mammary injection (TB). Cefquinoxime sulfate mammary injection was diluted according to the clinical dosage and the mouse-to-cow body weight ratio, and 100 μL was administered into each mammary duct for 7 consecutive days. OA, TAX, OA+TAX, and OA-TAX NPs were administered via mammary ducts at an effective in vitro inhibitory concentration of 32 μg / mL for 7 consecutive days. Mammary tissue was removed from three mice 1 day and 7 days after the end of administration. The separated mammary tissue from one side was fixed and sectioned. Paraffin blocks were sectioned using a microtome to obtain sections 4–6 μm thick, then mounted on glass slides and stained with hematoxylin and eosin (H&E). Each sample was examined for necrosis, polymorphonuclear neutrophils, and lymphocytic inflammation. Additionally, 100 mg of breast tissue (from the other side) was weighed and homogenized in 1 mL of sterile PBS using a tissue homogenizer. 50 μL of the homogenized tissue was pipetteed and serially diluted 10-fold (with PBS). The diluted tissue homogenate was then evenly spread onto LB agar plates using a sterile plate spreader and incubated overnight at 37°C, inverted. Plates at countable dilution concentrations were read, and CFU in the breast tissue was determined according to the dilution factor.

[0134] 5.2 Results

[0135] 5.2.1 Bacterial load in breast tissue

[0136] Bacterial load in breast tissue of different treatment groups, such as Figure 7 As shown. By Figure 7 It was found that, in the S. aureus count of mouse mammary tissue from different treatment groups, on day 1 after the end of drug administration, the OA, OA+TAX, OA-TAX NPs, and TB groups all showed effective bactericidal effects compared to S. aureus. However, the TAX group maintained a high bacterial load, indicating that TAX mainly inhibited S. aureus from entering the cell, but had a poor antibacterial effect on S. aureus. On day 7 after the end of drug administration, the bacterial load in the drug-treated groups continued to decrease, and the TB group had the fewest remaining colonies.

[0137] 5.2.2 Pathological changes in breast tissue

[0138] Pathological changes in breast tissue in different treatment groups, such as Figure 8As shown, the breast tissue structure in the S. aureus-infected control group was moderately abnormal, with obvious calcium salt deposition in some alveoli (as indicated by red arrows) and a small amount of inflammatory cell infiltration (as indicated by yellow arrows). The breast tissue structure in the OA group was mildly abnormal, with a small amount of inflammatory cell infiltration (as indicated by yellow arrows). The breast tissue structure in the TAX group was moderately abnormal, with mild fatty degeneration in some glandular epithelial cells and round vacuoles of varying sizes in the cytoplasm (as indicated by blue arrows); a small amount of inflammatory cell infiltration (as indicated by yellow arrows). The breast tissue structure in the OA+TAX group was mildly abnormal; obvious calcium salt deposition was observed in some alveoli (as indicated by red arrows). The breast tissue structure in the OA-TAXNPs group was basically normal, with abundant adipose and connective tissue, intact alveolar structure, and neatly and tightly arranged epithelial cells; no inflammatory cell infiltration was observed. The breast tissue structure in the TB group was mildly abnormal; the breast tissue in the field of view was in a quiescent phase, with underdeveloped glands, only a small number of small alveoli and ducts; a small number of inflammatory cells were observed in some ducts (as indicated by green arrows). In summary, this invention successfully prepared nanoparticles that can inhibit the invasive effects of *S. aureus* while effectively reducing the intracellular number of *S. aureus*. This will undoubtedly maximize the reduction of intracellular *S. aureus* numbers and will also benefit the use of natural drugs in veterinary clinical practice. Furthermore, the self-assembled nanoparticles of natural active molecules can regulate the polarization of RAW264.7 cells from the M1 phenotype to the M2 phenotype, reducing the secretion of pro-inflammatory cytokines, thereby helping to reduce inflammation. Moreover, the self-assembled nanoparticles 10 inhibited the growth of 86.7% of bacteria in mouse mammary tissue. Although the antibacterial effect of the self-assembled nanoparticles 10 is not as good as that of cefquinome sulfate intramuscular injection (TB), its anti-inflammatory effect is more advantageous.

[0139] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.

Claims

1. A self-assembling nanoparticle, characterized in that, The self-assembled nanoparticles, by mass percentage, consist of 0.17-0.24% natural active molecular composition, 1.5-2.25% stabilizer, 25% solvent, and the balance water. The natural active molecular composition is a combination of taxanol and oleanolic acid.

2. The self-assembled nanoparticle of claim 1, wherein, The natural active molecular composition is a composition of taxane and oleanolic acid in a mass ratio of (3.8-15.2):22.

8.

3. The self-assembled nanoparticle of claim 1, wherein, The stabilizer is one of polyvinyl alcohol, poloxamer 188, and polyvinylpyrrolidone.

4. The self-assembled nanoparticle of claim 1, wherein, The solvent is one of methanol, dimethyl sulfoxide, ethanol, and isopropanol.

5. A method of preparing the self-assembling nanoparticles of any one of claims 1-4, wherein, Includes the following steps: Taxol and oleanolic acid were dissolved in a solvent to obtain solution A. Solution A was then added dropwise to a stabilizer aqueous solution, and the mixture was sonicated and stirred to obtain the self-assembled nanoparticles.

6. The preparation method according to claim 5, characterized in that, The dripping process specifically involves adding water at a speed of 1.0-2.0 mL / min while stirring at a speed of 400-800 r / min; the ultrasonic treatment specifically involves ultrasonic treatment at a power of 180-360 W for 2-5 min; and the stirring time is 6-18 h.

7. Use of the self-assembled nanoparticles of any one of claims 1-4 in the preparation of a medicament for treating an intracellular bacterial infection or for reducing inflammation in a bacterial infection. The bacteria in question is Staphylococcus aureus.

Citation Information

Patent Citations

  • Natural small molecule co-assembled nano-drug delivery system as well as preparation method and application thereof

    CN111632032A

  • Pinoresinol diglucoside composition for improving microcirculation and preparation method thereof

    CN114404433A

  • Nanometer oleanolic acid powder for injection and preparation method thereof

    CN1628682A